
1 beb Driffmayo



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:		Docket No.:	4258-122
Applicants:	GEERLINGS, Arjian, et al.	Conf. No.:	Not Yet Assigned
Application No.:	10/587,324	Art Unit:	Not Yet Assigned
Date Filed:	July 26, 2006	Examiner:	Not Yet Assigned
Title:	ANTIHYPERTENSIVE PEPTIDES	Customer No.:	23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, First Class Mailed under the provisions of 37 CFR 1.8.

Karin/Szypszak

September 28, 2006

Date of Mailing

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN U.S. PATENT APPLICATION NO. 10/587,324

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each non-patent reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

Steven J. Hultquist Reg. No. 28,021

Attorney for Applicants

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW Phone: (919) 419-9350

Fax: (919) 419-9354
Attorney File No.: 4258-122

Enclosures:

IDS Forms [1 pg(s).]
Non-Patent References [80 pgs.]

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 083284

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known		
Application Number	10/587,324	
Filing Date	7/26/2006	
First Named Inventor	Geerlings et al.	
Art Unit	Not yet assigned	
Examiner Name	Not yet assigned	
Attorney Docket Number	A258-122	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials* No.1	Number - Kind Code ² (if known) MM-DD-YYYY	Applicant of Cited Document	Figures Appear		
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite No. 1	Foreign Patent Document	DD-YYYY Applican	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	6	
	Country Code ³ - Number ⁴ - Kind Code ⁵ (in known)		Applicant of Cited Document			

Examiner	Date			
Signature	Considered			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	AA	ASANO, MINAO, ET AL., Inhibition of prolyl endopeptidase by synthetic peptide fragments of human beta-casein, Agric. Biol. Chem., 1991, Page(s) 825-828, Volume 55, Number 3			
	AB	KOHMURA, MASANORI, ET AL., Inhibition of angiotensin-converting enzyme by synthetic peptides of human beta-casein, Agric. Biol. Chem., August 1989, Page(s) 2107-2114, Volume 53, Number 8			
	AC	LACOMBE, J.M., ET AL., Malaria invasion of human erythrocytes, Int. J. Peptide Protein Res., 1988, Page(s) 104-116, Volume 32			
	AD	SVENDSEN, I., Chemical modifications of the subtilisins with special reference to the binding of large substrates. A review., Carlesberg Res. Commun., 1976, Page(s) 237-291, Volume 41, Number 5			

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.